Pleural effusion as a significant prognostic factor in non-small cell lung cancer
- PMID: 9494600
Pleural effusion as a significant prognostic factor in non-small cell lung cancer
Abstract
In non-small cell lung cancer (NSCLC), pleural effusion is a frequently observed complication, and often provides a treatment difficulties. The aim of this study is to evaluate prognostic significance of pleural effusion in patients with NSCLC.
Materials and methods: Seven hundred and eight untreated patients with NSCLC who were consecutively admitted to our department over a 20 year period up to December 1996, were analyzed using uni- and multivariate analyses.
Results: Univariate analysis showed pleural effusion to be a significant prognostic factor for NSCLC, in addition to gender, stage, performance status(PS). Multivariate analysis proved pleural effusion to be one of the significant prognostic factors, especially in patients with poor PS.
Conclusion: Adequate palliative care to provide prolonged quality survival remains the primary goal of therapy for patients with poor performance status and pleural effusion until better treatments are developed.
Similar articles
-
Prognostic value of pleural effusion in patients with non-small cell lung cancer.Clin Cancer Res. 1997 Jan;3(1):47-50. Clin Cancer Res. 1997. PMID: 9815536
-
Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients.Ann Thorac Surg. 2006 Jan;81(1):298-304. doi: 10.1016/j.athoracsur.2005.06.073. Ann Thorac Surg. 2006. PMID: 16368385
-
Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?Ann Thorac Surg. 2005 Jan;79(1):254-7; discussion 254-7. doi: 10.1016/j.athoracsur.2004.06.115. Ann Thorac Surg. 2005. PMID: 15620952
-
[Interferon therapy of the lung and locoregional therapy in pulmology].Wien Med Wochenschr. 1993;143(16-17):450-4. Wien Med Wochenschr. 1993. PMID: 7505989 Review. German.
-
The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions.Clin Lung Cancer. 2007 Nov;8(9):535-47. doi: 10.3816/CLC.2007.n.040. Clin Lung Cancer. 2007. PMID: 18186958 Review.
Cited by
-
Adequacy of pleural fluid cytology for comprehensive molecular analysis of lung adenocarcinoma: Experience of a large health-care system.Cytojournal. 2022 Feb 4;19:7. doi: 10.25259/Cytojournal_18_2021. eCollection 2022. Cytojournal. 2022. PMID: 35510120 Free PMC article.
-
Surgical treatment in malignant pleural effusion.Turk Gogus Kalp Damar Cerrahisi Derg. 2021 Oct 20;29(4):577-585. doi: 10.5606/tgkdc.dergisi.2021.20580. eCollection 2021 Oct. Turk Gogus Kalp Damar Cerrahisi Derg. 2021. PMID: 35096460 Free PMC article. Review.
-
Important prognostic factors for survival in patients with malignant pleural effusion.BMC Pulm Med. 2015 Mar 28;15:29. doi: 10.1186/s12890-015-0025-z. BMC Pulm Med. 2015. PMID: 25887349 Free PMC article.
-
Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions.J Thorac Dis. 2014 May;6(5):483-90. doi: 10.3978/j.issn.2072-1439.2014.02.14. J Thorac Dis. 2014. PMID: 24822107 Free PMC article.
-
Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone.J Thorac Dis. 2020 May;12(5):2499-2506. doi: 10.21037/jtd.2020.03.49. J Thorac Dis. 2020. PMID: 32642157 Free PMC article.